Cassava Sciences shares fall after SEC charges for misleading Alzheimer's drug trial claims
Shares of Cassava Sciences fell 10% in post-market trading on Thursday after the U.S. Securities and Exchange Commission ...
Cassava Sciences settles SEC charges of ‘misleading’ Alzheimer’s trial claims
Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday after announcing a settlement with U.S ...
US charges Cassava Sciences, two former executives for misleading claims about Alzheimer’s clinical trial
The U.S. Securities and Exchange Commission said on Thursday that it charged Cassava Sciences and two of the company's former ...
SEC Charges Cassava Sciences, Two Former Executives for Misleading Claims About Alzheimer’s Clinical Trial
The Securities and Exchange Commission today announced Cassava Sciences, Inc., its founder and former CEO, Remi Barbier, and ...
Cassava Sciences Resolves SEC Investigation
AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company ...
SEC Announces $40 Mln Settlement With Cassava Sciences Over Misleading Alzheimer's Trial Statements
The U.S. Securities and Exchange Commission announced Cassava Sciences Inc. (SAVA), its founder and former CEO, Remi Barbier, and its ...
Alzheimer’s Drug Developer Cassava Paying $40 Million to Settle Doctored Data Claims
The Securities and Exchange Commission alleged that a researcher for the company manipulated trial data to make its drug ...
SEC Charges Cassava Sciences, Former Executives for Misleading Claims in Alzheimer's Trial
Cassava Sciences and two former executives will pay more than $40 million to settle charges related to misleading statements made about a clinical trial for the company's purported therapeutic ...
Cassava's Simufilam: Safe On The Outside, Scrambled On The Inside
Cassava's financial challenges and data integrity concerns remain critical. Learn why SAVA stock is rated a strong sell given ...
Why I'm Avoiding Cassava Stock For Now
Cassava Sciences' stock rose 9% after completing a trial of its Alzheimer's drug, Simufilam, but the company's future remains ...
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials.The DSMB Recommended ...
Stockhouse2d
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
The first Phase 3 trial (NCT04994483) has a 52-week treatment period ... About Cassava Sciences, Inc. Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is ...